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Four peptides present in completely different biological sources have been shown to exhibit a large degree of structural 
similarity. The peptides include: (i) a 60 amino acid residue breast cancer associated pS2 peptide isolated from human 
gastric juice and the culture media of the human breast cancer cell line MCF-7; (ii) a 106 amino acid residue pancreatic 
spasmolytic polypeptide (PSP) isolated from porcine pancreas and pancreatic juice; and (iii) a 49 and 50 amino acid resi- 
due peptide predicted from a cDNA isolated from the skin of the frog, Xenopus luevis. These peptides are characterized 
by having one (pS2 and the frog peptides) or two (PSP) domains of a highly conserved 38-39 amino acid residue consen- 
sus sequence not found in any other known peptides or proteins. The domain sequences contain 6 cysteine residues in 
nearly the same positions and it is suggested that these 6 residues are linked by 3 disulphide bonds to form a characteristic 
‘trefoil’ disulphide loop structure common in all four peptides. From the sources of which the peptides have been isolated 
and from experiments showing that PSP has a growth factor stimulatory effect on MCF-7 cells, it is further suggested 
that these peptides may represent members of a new family of growth factors. 
Amino acid sequence comparison; Domain structure; Disuhide bond; Receptor binding 
1. INTRODUCTION 
A significant number of peptides with growth 
stimulatory effects on mammalian cells have been 
isolated and characterized over the last 15 years. 
These peptides include epidermal growth factor 
(EGF) [l], transforming growth factor alpha 
(TGFcu) [2], transforming growth factor beta 
(TGFfl) [3], platelet-derived growth factor (PDGF) 
[4], insulin-like growth factors (IGF-I and IGF-II) 
P-71, nerve growth factor [8], and heparin- 
binding growth factor (acidic fibroblast growth 
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factor) [9]. These peptides are all characterized by 
having a certain number of cysteine residues linked 
by inter or intra chain disulphide bonds. The 
detailed disulphide bond configuration which is 
important for the tertiary structure and biological 
activity of the molecules has been elucidated for 
EGF, TGFa and IGF-I. These peptides all contain 
three disulphide bonds in a region comprising 36 
(TGFa), 37 (EGF) or 56 (IGF-I) amino acid 
residues [1,2,5-71. If the cysteine residues are 
numbered from the N-terminal end, EGF and 
TGFcv have a disulphide bonding of 1-3, 2-4 and 
5-6 [lO,l I] whereas IGF-I is believed to have a 
disulphide bonding of l-4, 2-6, and 3-5 [12]. In the 
present paper I wish to suggest he existence of a 
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new family of growth factors characterized by hav- 
ing one or two domains, in which each domain 
consists of 38 or 39 amino acid residues and three 
disulphide bonds in the configuration of either l-5, 
2-4, 3-6 or l-4, 2-5, 3-6. In either case, the 
disulphide bond configuration is different from 
the one in EGF/TGFcz and IGF-I. The members of 
the new family constitute human breast cancer 
associated peptide (pS2), pancreatic spasmolytic 
polypeptide (PSP), and two frog skin peptides 
(spasmolysin I and II). 
2. THE pS2 PEPTIDE 
The gene encoding the human pS2 peptide has 
been discovered by differential screening of a 
cDNA library obtained from the human breast 
cancer cell line MCF-7 induced by estrogen 
[13,14]. The pS2 gene has been cloned by two 
groups [ 15,161. The nucleotide sequence of a pS2 
full-length cDNA encoded a peptide of 84 amino 
acid residues out of which 26 or 21 residues 
represented a putative signal peptide correspon- 
ding to a mature pS2 peptide of 58 or 63 residues 
[15]. By the use of an antibody raised against a 
synthetic peptide corresponding to a 3 1 amino acid 
residue sequence from the C-terminal end of the 
predicted pS2 peptide, it has been possible to 
immuno-precipitate the pS2 peptide from the 
culture media of MCF-7 cells [ 171. Amino acid 
labelling experiments indicated that the pS2 pep- 
tide is secreted as a 58 amino acid residue peptide 
[17]. The pS2 peptide is present in the culture 
media of MCF-7 cells after estrogen induction at a 
concentration of 30- 100 pug/l [ 18,191. Recently, it 
has been possible to purify a sufficient amount of 
the peptide from this source for gas-phase protein 
sequencing. These analyses showed that the pS2 
peptide is secreted from the MCF-7 cells as a 60 
amino acid residue peptide [18,19]. By use of the 
above mentioned pS2 antibodies, a large variety of 
human tissues (including normal breast tissue and 
pancreas) has been screened for pS2-specific stain- 
ing [20]. The pS2 peptide was found to be 
specifically expressed and secreted by the mucosa 
cells of the human stomach, and the concentration 
in the gastric juice was 30-100 pg/l [20]. Analysis 
of the purified gastric pS2 peptide indicated that 
the first 48 amino acid residues are identical to 
those of the secreted MCF-7 pS2 peptide, although 
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the N-terminal amino acid residue of the gastric 
peptide may be present as a pyroglutamic acid [ 191. 
However, the MCF-7 pS2 peptide and the gastric 
pS2 peptide do not show a completely identical 
tryptic mapping [19], and it cannot be excluded 
that the gastric peptide has some C-terminal post- 
translational modification (e.g. at Cys-58) dif- 
ferent from that of the MCF-7 pS2 peptide. 
The reason for the presence of the pS2 peptide 
in breast cancer cells and in the human gastric juice 
is unknown. Neither the pS2 peptide nor the pS2 
mRNA have been found in significant amounts in 
normal breast tissue of women [21]. The pS2 pep- 
tide is also absent from the breast tissue late in 
pregnancy, during lactation, and in human milk 
[20]. The possibility of the pS2 peptide being an 
autocrine growth factor for MCF-7 cells has been 
examined by Davidson et al. [22]. From the study 
of the pS2 gene expression in two variants of 
MCF-7 cells they concluded that the pS2 peptide 
did not seem to play a role as a major autocrine 
growth factor [22]. However, the effect of the pS2 
peptide on the growth of MCF-7 cells or other 
mammalian cells has not been investigated, and the 
possibility of the pS2 peptide being a paracrine 
growth factor still exists. 
3. PANCREATIC SPASMOLYTIC 
POLYPEPTIDE 
Pancreatic spasmolytic polypeptide (PSP) was 
originally discovered in a side fraction from the 
purification of porcine insulin [23]. The concentra- 
tion of PSP in porcine pancreas is approx. 
100 mg/kg [24], which is about half the content of 
insulin. The initial characterization of the peptide 
showed that it contains 106 amino acid residues in 
a single chain; the peptide is N-terminally blocked 
and heavily crosslinked by seven disulphide bridges 
[23]. In 1985, the complete amino acid sequence of 
PSP was published [25]. These studies showed that 
PSP is composed of two homologous domains 
probably derived from a common gene [25]. 
Recently, the amino acid sequence of PSP has been 
revised at four positions using a combination of 
mass spectrometry and Edman degradations [26]. 
The presence of a N-terminal pyroglutamic acid 
residue was also confirmed in this study [26]. The 
amino sequence of PSP is given in fig. 1, which also 
shows the large degree of similarity between the 
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Fig. 1. Alignment of the amino acid sequences for the human 
breast cancer associated pS2 peptide [15,16,18,19], porcine 
pancreatic spasmolytic polypeptide domain I and II [25,26], 
and the frog skin peptides spasmolysin I and II [35]. It should 
be noted that Gln-1 1 of PSP-domain I has been deleted in order 
to obtain exact alignment of cysteine residues. The suggested 
disulphide bond configuration is shown for the domain 
consensus equence. 
two domains of the molecule. In the two PSP do- 
mains (PSP(8-47) and PSP(58-96)), 19 out of 39 
residues are identical. 
Studies have been initiated to determine the 
disulphide bond configuration of PSP. These 
studies are rendered difficult by the remarkable 
resistance of the native PSP to proteolytic diges- 
tion [27]. By a combination of CNBr-treatment 
followed by thermolysin digestion it has been 
possible to divide the native PSP into two separate 
moieties; one containing residues l-55 disulphide 
linked to residues loo-106 and another comprising 
residues 56-58 disulphide linked to residues 
61-95. By further trypsin digestion of the latter 
fragment, a three chained and a two chained 
molecule was obtained; the three chained molecule 
comprises the residues 56-58, 62-72, and 79-84, 
and the two chained molecule comprises the 
residues 73-78 and 85-95 (Christensen, M., per- 
sonal communications). From these results the 
disulphide bond configuration of PSP-domain II is 
either A: 78-95, 68-83, 58-84 or B: 78-95, 68-84, 
58-83. Preliminary data from Edman degradation 
of the three chained molecule suggest possibillty A. 
By homology to domain II the disulphide bond 
configuration in PSP-domain I (see fig.1) is either 
A: 29-46, 19-34, 8-35, or B: 29-46, 19-35, 8-34. 
Assuming possibility A, the entire structure of PSP 
including the seven disulphide bond can be deduc- 
ed (fig.2). It should be emphasized that from the 
preliminary experimental data presently available 
Fig.2. Proposed structure of porcine pancreatic spasmolytic 
polypeptide (PSP). 
possibility B (‘cross-over’ of two disulphide bonds 
in each domain) cannot be excluded. 
Several studies have been carried out to elucidate 
the possible physiological function of PSP. In ex- 
tracts from 22 different porcine tissues the pan- 
creas was found to be the only organ containing 
substantial amounts of PSP [24]. After stimulation 
with pancreozymin or secretin, large amounts of 
PSP (So-100 mg/l) were found to be secreted into 
the pancreatic juice, indicating that PSP is related 
to the exocrine function of the pancreas [24]. A 
pharmacological screening has indicated that PSP 
has spasmolytic, and gastric acid secretion in- 
hibitory effects [28]. Although we were not com- 
pletely certain that these effects reflected the 
physiological functions of the peptide, we decided 
to name it pancreatic spasmolytic polypeptide. 
Specific binding of PSP to rat intestinal mucosa 
cells and membrane preparations from these cells 
have been demonstrated [29,30]. These binding 
studies showed the presence of high-affinity, low- 
capacity sites (dissociation constant: 130 nM), and 
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low-affinity, high-capacity sites (dissociation con- 
stant 4.2 ,uM) [29]. The presence of PSP recogni- 
tion sites (receptors) on intestinal mucosa cells in 
combination with the high concentration of PSP in 
pancreatic juice [24] and the remarkable resistance 
towards proteolytic digestion [27] suggests a 
unique intraluminal function of the peptide. 
Recently, it has been shown that PSP has growth 
stimulatory effect on the colon carcinoma cell, 
HCT 116, and the human breast cancer cell, 
MCF-7 [31]. The growth stimulatory effect of por- 
cine PSP on human MCF-7 cells could very likely 
be due to cross-recognition with a pS2 site [31], 
thus indicating a very closely related tertiary struc- 
ture of the porcine PSP and the human pS2 
peptide. 
4. SPASMOLYSIN I AND II 
The amphibian skin has proven to be a valuable 
source for the isolation of new biological active 
peptides [32]. Thus peptides isolated from amphib- 
ian skin often have been found to have their 
counterpart in the brain and gut of mammalians. 
This has been the case with the cholecystokinin/ 
gastrin-like peptide caerulein [33] and the 
neurotensin-like peptide xenopsin [34]. 
Recently, a new protein from the skin of the frog 
Xenopus laevis, highly homologous to PSP and 
pS2 has been cloned [35]. Processing at two dibasic 
sequences in N- and C-terminal parts of the 
molecule would lead to the generation of two pep- 
tides consisting of 49 and 50 amino acid residues, 
respectively [35]. Both of these peptides 
(spasmolysin I and II) contain 6 half-cystine 
residues, and the sequences are highly homologous 
to the pS2 peptide and the two domains of PSP 
[35] (fig.1). The biological function of these pep- 
tides in the frog skin is unknown. Due to their 
structural similarities with PSP/pS2 and their co- 
existence with biological active peptides in the frog 
skin it is tempting to suggest hat spasmolysin I
and II have a growth stimulatory effect on at least 
some of the cells in the frog skin. 
5. SEQUENCE COMPARISON 
Fig.1 shows a comparison of the sequences of 
the pS2 peptide, PSP and the frog skin peptides. 
The sequence of the 60 amino acid residue pS2 
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peptide is taken from [15,16,18,19]. The N- 
terminal amino acid residue (Z) is glutamic acid in 
the pS2 peptide isolated from the culture media of 
MCF-7 cells [l&19] and probably pyroglutamic 
acid in the pS2 peptide isolated from human 
gastric juice [19]. The sequence of PSP is taken 
from [26], in which the original PSP sequence [25] 
was revised at four positions. The N-terminal 
amino acid residue (Z) is pyroglutamic acid 
[25,26]. The 106 amino acid residue PSP has been 
divided into two homologous domains, PSP-I 
(residue l-55) and PSP-II (residue 56-106). The 
sequences of the frog skin peptides (spasmolysin I 
and II) have been taken from [35] assuming pro- 
cessing of the ‘spasmolysin precursor’ at Ala-20, 
Gln-21 (signal peptidase) and at the two dibasic se- 
quences Lys-70, Lys-71 and Arg-349, Lys-350 as 
suggested by Hoffmann [35]. With the exception 
of a single residue (e.g. Gln-11) in PSP-domain I 
it is possible to align all five domains without in- 
troducing gaps or insertions in a configuration 
which places all of the 6 half-cystine residues in ex- 
actly the same positions (fig.1). This surprising se- 
quence homology has previously been noticed 
[35-371. Besides some rather weak homology to 
the kringle regions of plasminogen [25,36], a 
search in the latest version (Ver. 19, updated 
February 1989) of the Dayhoff protein sequence 
database (National Biomedical Research Founda- 
tion, Georgetown, Washington DC, USA) using 
the programs SEARCH, RELATE and FASTP 
[38] did not pick up any protein or peptide with 
significant homology to the domain structures 
(author’s observation). 
From the alignments it is possible to deduce a 
domain consensus sequence comprising 38 or 39 
amino acid residues (fig.1). 
6. ‘TREFOIL’ DISULPHIDE LOOP 
STRUCTURES 
Although it is possible to align the individual do- 
mains (fig.1) two by two to obtain a larger degree 
of homology, it is highly probable that the con- 
served part constitutes the six half-cystine residues 
and may be the Trp-Cys-Phe sequence in the C- 
terminal part of the domains. Thus the conserved 
element seems to be more related to the disulphide 
bond configuration and the number of residues in 
the three loop (the secondary and tertiary struc- 
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Fig.3. Proposed structure of human breast cancer associated 
pS2 peptide. 
ture) than it is to the exact nature of the amino acid 
residues within the individual loops. Although the 
disulphide bond configuration is unknown for the 
pS2 peptide and frog peptides and only tentatively 
known for PSP as previously discussed, the se- 
quence alignments have prompted me to suggest a 
trefoil disulphide loop structure common in all five 
domains (fig.4). From this structure, which is 
based on the preliminary assignment of disulphide 
bonds in PSP (fig.2), it is possible to suggest he 
structure of the pS2 peptide (fig.3) and the frog 
skin peptides (not shown). 
Using antibodies against porcine PSP, no 
significant amount of immunoreactive material 
could be detected in human pancreatic extract or 
pancreatic juice (author’s observation). It is in- 
teresting to note that also the human pS2-specific 
antibodies did not pick up any pS2-like material in 
the human pancreas [20]. As extracts from the 
human stomach, human gastric juice or MCF-7 
cell media have not been investigated using the 
porcine PSP antibodies, the possible immuno- 
chemical cross-reactivity between the human pS2 
peptide and the porcine PSP still needs to be 
determined. 
However, the observed growth stimulatory ef- 
fect of porcine PSP on human MCF-7 cells may be 
mediated by a recognition site (receptor) specific 
for the trefoil structure of PSP and pS2 [31]. This 
recognition site may be similar to the PSP-binding 
site (receptor) identified in rat mucosa cells and 
membrane preparations from these cells [29,30]. 
Although cross-recognition between the pS2 pep- 
tide and PSP may exist on the receptor level, fur- 
ther studies are needed to fully evaluate to which 
degree the suggested structural similarities of the 
pS2 peptide, the PSP, and the frog skin peptide 
imply similar biological effects such as growth 
stimulation. 
Fig.4. The ‘trefoil’ disulphide loop structure suggested as a common feature in the pS2 peptide, PSP and the frog skin peptides. 
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